BioXcel Therapeutics (NASDAQ:BTAI – Free Report) had its price objective cut by HC Wainwright from $7.00 to $5.00 in a research report report published on Monday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q3 2024 earnings at ($0.55) EPS, Q4 2024 earnings at ($0.49) EPS, FY2024 earnings at ($2.03) EPS, Q1 2025 earnings at ($0.45) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at ($0.28) EPS and FY2025 earnings at ($1.54) EPS.
BTAI has been the topic of a number of other research reports. Canaccord Genuity Group reissued a “buy” rating and issued a $7.00 price target on shares of BioXcel Therapeutics in a research note on Friday, August 30th. UBS Group dropped their target price on shares of BioXcel Therapeutics from $3.50 to $1.00 and set a “neutral” rating on the stock in a research report on Friday, August 9th.
Read Our Latest Research Report on BTAI
BioXcel Therapeutics Stock Performance
BioXcel Therapeutics (NASDAQ:BTAI – Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.55. The company had revenue of $1.10 million for the quarter, compared to the consensus estimate of $0.80 million. During the same period in the prior year, the business earned ($1.83) earnings per share. On average, sell-side analysts expect that BioXcel Therapeutics will post -1.84 EPS for the current fiscal year.
Institutional Investors Weigh In On BioXcel Therapeutics
A number of institutional investors have recently bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. purchased a new position in BioXcel Therapeutics during the 2nd quarter valued at about $39,000. Rosalind Advisors Inc. purchased a new position in BioXcel Therapeutics during the second quarter valued at approximately $51,000. XTX Topco Ltd grew its position in BioXcel Therapeutics by 49.0% during the second quarter. XTX Topco Ltd now owns 46,503 shares of the company’s stock valued at $60,000 after purchasing an additional 15,291 shares in the last quarter. Virtu Financial LLC acquired a new position in BioXcel Therapeutics in the 4th quarter valued at approximately $176,000. Finally, Vanguard Group Inc. lifted its position in BioXcel Therapeutics by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 1,099,375 shares of the company’s stock worth $3,100,000 after buying an additional 9,912 shares in the last quarter. 30.68% of the stock is currently owned by institutional investors and hedge funds.
BioXcel Therapeutics Company Profile
BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.
Featured Stories
- Five stocks we like better than BioXcel Therapeutics
- With Risk Tolerance, One Size Does Not Fit All
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- What Do S&P 500 Stocks Tell Investors About the Market?
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- How to Buy Cheap Stocks Step by Step
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.